Plant-derived medicines are prone to shortages because their agriculture-based supply chains are vulnerable to geopolitical and environmental factors.

Recreating biosynthesis of these medicines in a scalable organism like Baker’s yeast (Saccharomyces cerevisiae) provides an economical, resilient alternative to plant cultivation.

One such medicine is Tropane alkaloids (TAs), which are neurotransmitter receptor inhibitors produced by nightshade plants and are classified as essential medicines by the World Health Organization for treating neuromuscular disorders. In this webinar, we hear from Prashanth Srinivasan, who along with his colleagues at Stanford have developed a proof-of-concept ‘biomanufacturing’ platform for the production of TA medicines, hyoscyamine and scopolamine.

Results from customer experience are not predictive of other cases. Results in other cases may vary.